BW A868C
(Synonyms: 3-[(2-环己基-2-羟乙基)氨基]-2,5-二氧代-1-(苯甲基)-4-咪唑啶庚酸) 目录号 : GC17348A DP receptor antagonist
Cas No.:118675-50-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
BW A868C is a novel, selective and potent competitive antagonist of prostaglandin D2 (PGD2) [1].
Prostaglandin D2 has been widely distributed in rat brain, spinal cord and pituitary and may act as a neuromodulator in the central nervous system [2]. Prostaglandin D2 is critical for the development of allergic diseases such as asthma.
In vitro: In glycerol-lysed human platelets, BW245C activated adenylate cyclase in a biphasic manner. BW A868C showed no effect on carbacyclin, iloprost, prostacyclin, PGE1 and PGE2 at a concentration 1,000 fold that of its KB against PGD2 and BW245C [1]. BW A868C showed no effect on human TP, IP, EP1, EP2, and FP receptors. The Ki value for BW A868C is approximately 1.7 nM[1] .In isolated rings of rabbit saphenous vein (RbSV) pre-contracted with 40 mM KCl, BW245C caused concentration-dependent relaxations with an EC50 of 38 nM [3].
References:
[1] Giles H, Leff P, Bolofo M L, et al. The classification of prostaglandin DP‐receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist[J]. British journal of pharmacology, 1989, 96(2): 291-300.
[2] Shimizu T, Mizuno N, Amano T, et al. Prostaglandin D2, a neuromodulator[J]. Proceedings of the National Academy of Sciences, 1979, 76(12): 6231-6234.
[3] Lydford S J, McKechnie K C W, Leff P. Interaction of BW A868C, a prostanoid DP-receptor antagonist, with two receptor subtypes in the rabbit isolated saphenous vein[J]. Prostaglandins, 1996, 52(2): 125-139.
| Cas No. | 118675-50-6 | SDF | |
| 别名 | 3-[(2-环己基-2-羟乙基)氨基]-2,5-二氧代-1-(苯甲基)-4-咪唑啶庚酸 | ||
| 化学名 | 3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)-4-imidazolidineheptanoic acid | ||
| Canonical SMILES | O=C1C(CCCCCCC(O)=O)N(NCC(O)C2CCCCC2)C(N1CC3=CC=CC=C3)=O | ||
| 分子式 | C25H37N3O5 | 分子量 | 459.6 |
| 溶解度 | ≤20mg/ml in DMSO;20mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1758 mL | 10.879 mL | 21.7581 mL |
| 5 mM | 0.4352 mL | 2.1758 mL | 4.3516 mL |
| 10 mM | 0.2176 mL | 1.0879 mL | 2.1758 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。